ANXA3 plays pivotal roles in promoting cancer and stem cell-like features in CD133+ liver cancer stem cells (CSCs) through a dysregulated JNK pathway [40], and overexpression of ANXA3 suppresses apoptosis and promotes autophagic responses via PKCd/p38 MAPK signaling in sorafenib-resistant hepatocellular carcinoma cells (HCCs) [41]. Here, PRKCD is linked to hepatocellular carcinoma.